At a glance
- Originator Nonindustrial source
- Class Antidementias; Neuroprotectants
- Mechanism of Action Muscarinic M1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 15 Mar 2001 Discontinued-Preclinical for Alzheimer's disease in Israel (Unknown route)
- 25 Aug 1998 No-Development-Reported for Alzheimer's disease in Israel (Unknown route)
- 17 Apr 1996 New profile